Skip to main content

Advertisement

SpringerLink
Log in

A Multifunctional Hydrogel Delivers Gold Compound and Inhibits Human Lung Cancer Xenograft

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose

Interpenetrating network system (IPN), consisting of polyethylene glycol (PEG) –diacrylate (PEGdA) and modified gelatin, is a biocompatible and biodegradable hydrogel and has been studied for the local delivery of bioactive molecules and drugs. Gold(III) porphyrin(AuP) is a stable metal compound in the development for anticancer application when administered systemically. The aim of this work is to develop a novel formulation for AuP based on IPN for local delivery.

Methods

IPN loaded with AuP hydrogel was optimized and synthesized. Drug release kinetics, cytotoxicity against tumor cells, and antitumor activity in lung cancer bearing nude mice were studied.

Results

AuP released from the IPN followed a first order kinetics in vitro. The AuP loaded IPN showed higher cytotoxicity against human lung cancer cell lines compared to IPN only. In mice bearing human lung cancer xenograft, AuP loaded IPN inhibited tumor growth and reduced angiogenesis. No sign of systemic toxicity was observed for all treatment groups.

Conclusion

AuP loaded IPN provides an improved formulation over systemic delivery for tumor inhibition to complement surgical intervention.

Injectable multifunctional matrix of polyethylene glycol and gelatin derivatives for the delivery of gold porphyrinto inhibit tumor growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Vintiloiu A, Leroux JC. Organogels and their use in drug delivery - a review. J Control Release. 2008;125(3):179–92.

    Article  CAS  Google Scholar 

  2. [Internet] World Health Organization (Feb 2018). Fact sheets. Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/

  3. Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, Brawley OW. An assessment of progress in cancer control. CA Cancer J Clin. 2018;68(5):329–39.

    Article  Google Scholar 

  4. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.

    Article  CAS  Google Scholar 

  5. [Internet] American Cancer Society (May 2018). https://www.cancer.org/cancer/non small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html.

  6. Yegya-Raman N, Zou W, Nie K, Malhotra J, Jabbour SK. Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy. J Thorac Dis 2018;10(Suppl 21):S2474-S91, S2491.

  7. Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaka Y, Okuda K, et al. Prognosis of recurrent non-small cell lung cancer following complete resection. Oncol Lett. 2014;7(4):1300–4.

    Article  Google Scholar 

  8. Wu W, Chen H, Shan F, Zhou J, Sun X, Zhang L, et al. A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery. Mol Pharm. 2014;11(10):3378–85.

  9. Norouzi M, Nazari B, Miller DW. Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov Today. 2016;21(11):1835–49.

    Article  CAS  Google Scholar 

  10. Bruijnincx PC, Sadler PJ. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol. 2008;12(2):197–206.

    Article  CAS  Google Scholar 

  11. Basu U, Banik B, Wen R, Pathak RK, Dhar S. The Platin-X series: activation, targeting, and delivery. Dalton Trans. 2016;45(33):12992–3004.

    Article  CAS  Google Scholar 

  12. Li XJ, Liu YH, Tian HQ. Current developments in Pt(IV) prodrugs conjugated with bioactive ligands. Bioinorg Chem Appl. 2018;2018:1–18.

    Article  Google Scholar 

  13. Nardon C, Pettenuzzo N, Fregona D. Gold complexes for therapeutic purposes: an updated patent review (2010-2015). Curr Med Chem. 2016;23(29):3374–403.

    Article  CAS  Google Scholar 

  14. Bindoli A, Rigobello MP, Scutari G, Gabbiani C, Casini A, Messori L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coordin Chem Rev. 2009;253(11–12):1692–707.

    Article  CAS  Google Scholar 

  15. Che CM, Sun RW, Yu WY, Ko CB, Zhu N, Sun H. Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem Commun (Camb). 2003;(14):1718–9.

  16. Sun RWYCCM. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Coord Chem Rev. 2009;253:1682–91.

    Article  CAS  Google Scholar 

  17. Chung CY, Fung SK, Tong KC, Wan PK, Lok CN, Huang Y, et al. A multi-functional PEGylated gold(iii) compound: potent anti-cancer properties and self-assembly into nanostructures for drug co-delivery. Chem Sci. 2017;8(3):1942–53.

    Article  CAS  Google Scholar 

  18. Lum CT, Liu X, Sun RW, Li XP, Peng Y, He ML, et al. Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro. Cancer Lett. 2010;294(2):159–66.

    Article  CAS  Google Scholar 

  19. To YF, Sun RW, Chen Y, Chan VS, Yu WY, Tam PK, et al. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int J Cancer. 2009;124(8):1971–9.

    Article  CAS  Google Scholar 

  20. Lum CT, Yang ZF, Li HY, Wai-Yin Sun R, Fan ST, Poon RT, et al. Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int J Cancer. 2006;118(6):1527–38.

    Article  CAS  Google Scholar 

  21. Tu S, Wai-Yin Sun R, Lin MC, Tao Cui J, Zou B, Gu Q, et al. Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer. Cancer. 2009;115(19):4459–69.

    Article  CAS  Google Scholar 

  22. Lum CT, Sun RWY, Zou TT, Che CM. Gold(III) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 gene. Chem Sci. 2014;5(4):1579–84.

    Article  CAS  Google Scholar 

  23. Zou TT, Lum CT, Lok CN, Zhang JJ, Che CM. Chemical biology of anticancer gold((III)) and gold((I)) complexes. Chem Soc Rev. 2015;44(24):8786–801.

    Article  CAS  Google Scholar 

  24. Wang Y, He QY, Sun RWY, Che CM, Chiu JF. Gold(III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 2005;65(24):11553–64.

    Article  CAS  Google Scholar 

  25. Hu D, Liu Y, Lai YT, Tong KC, Fung YM, Lok CN, et al. Anticancer gold(III) porphyrins target mitochondrial chaperone Hsp60. Angew Chem Int Ed Engl. 2016;55(4):1387–91.

  26. Lum CT, Huo L, Sun RW, Li M, Kung HF, Che CM, et al. Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis. Acta Oncol. 2011;50(5):719–26.

    Article  CAS  Google Scholar 

  27. Kim JH, Kim MS, Lee BH, Kim JK, Ahn EK, Ko HJ, et al. Marmesin-mediated suppression of VEGF/VEGFR and integrin beta1 expression: its implication in non-small cell lung cancer cell responses and tumor angiogenesis. Oncol Rep. 2017;37(1):91–7.

  28. Pu D, Liu J, Li Z, Zhu J, Hou M. Fibroblast growth factor receptor 1 (FGFR1), partly related to vascular endothelial growth factor receptor 2 (VEGFR2) and microvessel density, is an independent prognostic factor for non-small cell lung Cancer. Med Sci Monit. 2017;23:247–57.

    Article  CAS  Google Scholar 

  29. Gu Y, Korbel C, Scheuer C, Nenicu A, Menger MD, Laschke MW. Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model. Oncotarget. 2016;7(5):5258–72.

    Article  Google Scholar 

  30. Thambi T, Li Y, Lee DS. Injectable hydrogels for sustained release of therapeutic agents. J Control Release. 2017;267:57–66.

    Article  CAS  Google Scholar 

  31. Lin CC, Anseth KS. PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm Res-Dord. 2009;26(3):631–43.

    Article  CAS  Google Scholar 

  32. Echave MC, Saenz del Burgo L, Pedraz JL, Orive G. Gelatin as biomaterial for tissue engineering. Curr Pharm Des. 2017;23(24):3567–84.

    Article  CAS  Google Scholar 

  33. Guerra AD, Rose WE, Hematti P, Kao WJ. Minocycline enhances the mesenchymal stromal/stem cell pro-healing phenotype in triple antimicrobial-loaded hydrogels. Acta Biomater. 2017;51:184–96.

    Article  CAS  Google Scholar 

  34. Guerra AD, Yeung OWH, Qi X, Kao WJ, Man K. The anti-tumor effects of M1 macrophage-loaded poly (ethylene glycol) and gelatin-based hydrogels on hepatocellular carcinoma. Theranostics. 2017;7(15):3732–44.

    Article  CAS  Google Scholar 

  35. Xu K, Fu Y, Chung W, Zheng X, Cui Y, Hsu IC, et al. Thiol-ene-based biological/synthetic hybrid biomatrix for 3-D living cell culture. Acta Biomater. 2012;8(7):2504–16.

  36. Kleinbeck KR, Bader RA, Kao WJ. Concurrent in vitro release of silver sulfadiazine and bupivacaine from semi-interpenetrating networks for wound management. J Burn Care Res. 2009;30(1):98–104.

    Article  Google Scholar 

  37. Waldeck H, Kao WJ. Effect of the addition of a labile gelatin component on the degradation and solute release kinetics of a stable PEG hydrogel. J Biomat Sci-Polym E. 2012;23(12):1595–611.

    CAS  Google Scholar 

  38. Wang CH, Liu CJ, Wang CL, Hua TE, Obliosca JM, Le KH, et al. Optimizing the size and surface properties of polyethylene glycol (PEG)-gold nanoparticles by intense x-ray irradiation. J Phys D Appl Phys. 2008;41(19):195301.

    Article  Google Scholar 

  39. Fu Y, Xu K, Zheng X, Giacomin AJ, Mix AW, Kao WJ. 3D cell entrapment in crosslinked thiolated gelatin-poly(ethylene glycol) diacrylate hydrogels. Biomaterials. 2012;33(1):48–58.

    Article  CAS  Google Scholar 

  40. Yan JJ, Sun RW, Wu P, Lin MC, Chan AS, Che CM. Encapsulation of dual cytotoxic and anti-angiogenic gold(III) complexes by gelatin-acacia microcapsules: in vitro and in vivo studies. Dalton Trans. 2010;39(33):7700–5.

    Article  CAS  Google Scholar 

  41. Lee P, Zhu Y, Yan JJ, Sun RW, Hao W, Liu X, et al. The cytotoxic effects of lipidic formulated gold porphyrin nanoparticles for the treatment of neuroblastoma. Nanotechnol Sci Appl. 2010;3:23–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Lee P, Zhang R, Li V, Liu X, Sun RW, Che CM, et al. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine. 2012;7:731–7.

  43. He L, Chen T, You Y, Hu H, Zheng W, Kwong WL, et al. A cancer-targeted nanosystem for delivery of gold(III) complexes: enhanced selectivity and apoptosis-inducing efficacy of a gold(III) porphyrin complex. Angew Chem Int Ed Engl. 2014;53(46):12532–6.

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry and Chemical Biology Centre, The University of Hong Kong, Pokfulam, Hong Kong

    Puiyan Lee, Chun-Nam Lok, Chi-Ming Che & Weiyuan John Kao

  2. Department of Biomedical Engineering, The University of Hong Kong, Pokfulam, Hong Kong

    Weiyuan John Kao

  3. Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong

    Weiyuan John Kao

Authors
  1. Puiyan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chun-Nam Lok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chi-Ming Che
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weiyuan John Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chi-Ming Che or Weiyuan John Kao.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, P., Lok, CN., Che, CM. et al. A Multifunctional Hydrogel Delivers Gold Compound and Inhibits Human Lung Cancer Xenograft. Pharm Res 36, 61 (2019). https://doi.org/10.1007/s11095-019-2581-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11095-019-2581-z

Key words

Search

Navigation